The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
An anti-human interleukin 5 receptor (hIL-5R) humanized immunoglobulin G1 (IgG1) and an anti-CD20 chimeric IgG1 produced by rat hybridoma YB2/0 cell lines showed more than 50-fold higher antibody-dependent cellular cytotoxicity (ADCC) using purified human peripheral blood mononuclear cells as effector than those produced by Chinese hamster ovary (CHO) cell lines. Monosaccharide composition and oligosaccharide profiling analysis showed that low fucose (Fuc) content of complex-type oligosaccharides was characteristic in YB2/0-produced IgG1s compared with high Fuc content of CHO-produced IgG1s. YB2/0-produced anti-hIL-5R IgG1 was subjected to Lens culinaris aggulutin affinity column and fractionated based on the contents of Fuc. The lower Fuc IgG1 had higher ADCC than the IgG1 before separation. In contrast, the content of bisecting GlcNAc of the IgG1 affected ADCC much less than that of Fuc. In addition, the correlation between Gal and ADCC was not observed. When the combined effect of Fuc and bisecting GlcNAc was examined in anti-CD20 IgG1, only a severalfold increase of ADCC was observed by the addition of GlcNAc to highly fucosylated IgG1. Quantitative PCR analysis indicated that YB2/0 cells had lower expression level of FUT8 mRNA, which codes alpha1,6-fucosyltransferase, than CHO cells. Overexpression of FUT8 mRNA in YB2/0 cells led to an increase of fucosylated oligosaccharides and decrease of ADCC of the IgG1. These results indicate that the lack of fucosylation of IgG1 has the most critical role in enhancement of ADCC, although several reports have suggested the importance of Gal or bisecting GlcNAc and provide important information to produce the effective therapeutic antibody.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is ideal as increases in fucosylation have been correlated with decreased ADCC activity and decreased FcγRIIIa and FcγRIIb binding affinity. 40 , 41 , 42 , 43”
From Dynamic pH profiles drive higher cell‐specific and volumetric productivity (2026) · cites this paper as [42]
In the citing paper
“lower cell specific productivity has been shown to allow for more mature glycoforms, including G2F. 42”
From Dynamic pH profiles drive higher cell‐specific and volumetric productivity (2026) · cites this paper as [42]
In the citing paper
“Enriching the abundance of mAb N-glycoforms with β1,4-linked galactose (Gal) can also be desirable as it has been shown to enhance complement-dependent cytotoxicity (CDC), another mechanism for the selective depletion of tumour cells by Fc activation of the complement pathway [16–21].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [16]
In the citing paper
“The addition of bisecting β1,4-linked N-acetylglucosamine (GlcNAc) by endogenous or recombinant N-acetylglucosaminyltransferase III (GnT-III in YB2/0 and CHO cells respectively) or via in vitro glycan remodelling has also been linked to increased ADCC in IgGs, albeit to a lesser extent than afucosylation [15–17].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [16]
In the citing paper
“It was reported that afucosylated Fc domain glycans of human IgG1 could enhance the binding to FcγRIIIa subtype receptors of natural killer cells (Shields et al., 2002;Shinkawa et al., 2003;Niwa et al., 2005;Iida et al., 2006;Subedi and Barb, 2016).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Shinkawa et al., 2003
Citations
Cites
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Deisenhofer, J. (1981) · PubMed · Cited by 1,422
Deisenhofer, J. (1981) · Biochemistry · doi:10.1021/bi00512a001 · Cited by 1,333
Parekh, R. B., Dwek, R. A., Sutton, B. J., Fernandes, D. L., Leung, A., Stanworth, D., Rademacher, T. W., Mizuochi, T., Taniguchi, T., Matsuta, K., et al. (1985) · Nature · doi:10.1038/316452a0 · Cited by 1,170
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
Lewis, G. D., Figari, I., Fendly, B., Lee Wong, W., Carter, P., Gorman, C., & Shepard, H. M. (1993) · Cancer Immunology, Immunotherapy · doi:10.1007/bf01518520 · Cited by 498
Refined Structure of an Intact IgG2a Monoclonal Antibody,
Harris, L. J., Larson, S. B., Hasel, K. W., & McPherson, A. (1997) · Biochemistry · doi:10.1021/bi962514+ · Cited by 451
Crystallographic structure of an intact IgG1 monoclonal antibody 1 1Edited by I. A. Wilson
Harris, L. J., Skaletsky, E., & McPherson, A. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1508 · Cited by 440
Research works printed but not linked: 2
- Rademacher, 1986, Biochem. Soc. Symp., 51, 131
- Kumpel, 1994, Hum. Antib. Hybrid., 5, 143
Cited by
Items 501–600 of 1,000
Cardarelli, P. M., Rao‐Naik, C., Chen, S., Huang, H., Pham, A., Moldovan-Loomis, M.-C., Pan, C., Preston, B., Passmore, D., Liu, J., et al. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0746-z · Cited by 47
“Expression of antibodies in Ms-704PF CHO cells had previously been shown to result in antibodies deWcient in fucose [18, 24].”
Wang, Y., Fukuda, T., Isaji, T., Lu, J., Gu, W., Lee, H.-H., Ohkubo, Y., Kamada, Y., Taniguchi, N., Miyoshi, E., et al. (2015) · Scientific Reports · doi:10.1038/srep08264 · Cited by 54
Modulation of mAb quality attributes using microliter scale fed‐batch cultures
Rouiller, Y., Périlleux, A., Vesin, M., Stettler, M., Jordan, M., & Broly, H. (2014) · Biotechnology Progress · doi:10.1002/btpr.1921 · Cited by 53
Farzaneh, M., Hassani, S., Mozdziak, P. E., & Baharvand, H. (2017) · Biotechnology Journal · doi:10.1002/biot.201600598 · Cited by 51
“While CHO-produced antibodies contain α1,6-linked fucose on the core N-acetylglucosamine residue, the egg white-produced antibodies are not core-fucosylated [33, 39].”
BackgroundSun, D., Hu, F., Gao, H., Song, Z., Xie, W., Wang, P., Shi, L., Wang, K., Li, Y., Huang, C., et al. (2019) · The Analyst · doi:10.1039/c8an02014k · Cited by 52
Simultaneous Immunoglobulin A and G Glycopeptide Profiling for High-Throughput Applications
Momčilović, A., de Haan, N., Ederveen, A. L. H., Bondt, A., Koeleman, C. A. M., Falck, D., de Neef, L. A., Mesker, W. E., Tollenaar, R. A. �. �., de Ru, A., et al. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.9b05722 · Cited by 51
Brain Delivery of Nanomedicines: Trojan Horse Liposomes for Plasmid DNA Gene Therapy of the Brain
Pardridge, W. M. (2020) · Frontiers in Medical Technology · doi:10.3389/fmedt.2020.602236 · Cited by 46
“Owing to host cell-dependent fucosylation of the MAb, an antibody produced in myeloma cells may have a 50- to 100fold higher effector function than the same MAb produced in CHO cells (219, 223).”
BackgroundCD20-Directed Small Modular Immunopharmaceutical, TRU-015, Depletes Normal and Malignant B Cells
Hayden-Ledbetter, M. S., Cerveny, C., Espling, E., Brady, W., Grosmaire, L. S., Tan, P., Bader, R., Slater, S., Nilsson, C. A., Barone, D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1694 · Cited by 46
Characterization of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori)
Tada, M., Tatematsu, K., Ishii‐Watabe, A., Harazono, A., Takakura, D., Hashii, N., Sezutsu, H., & Kawasaki, N. (2015) · mAbs · doi:10.1080/19420862.2015.1078054 · Cited by 48
Control of galactosylated glycoforms distribution in cell culture system
McCracken, N. A., Kowle, R. L., & Ouyang, A. (2014) · Biotechnology Progress · doi:10.1002/btpr.1906 · Cited by 57
Highly Efficient Synthesis of Multiantennary Bisected N‐glycans Based on Imidates
Mönnich, M., Eller, S., Karagiannis, T., Perkams, L., Luber, T., Ott, D., Niemietz, M., Hoffman, J., Walcher, J., Berger, L., et al. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201604190 · Cited by 46
Fuji, S., & Shindo, T. (2016) · Stem Cell Investigation · doi:10.21037/sci.2016.09.13 · Cited by 47
“Moga, a monoclonal antibody that targets the chemokine receptor CCR4, was developed in Japan (20,21).”
BackgroundSubstrate Preference and Interplay of Fucosyltransferase 8 and N-Acetylglucosaminyltransferases
Tseng, T.-H., Lin, T.-W., Chen, C., Chen, C., Lin, J., Hsu, T.-L., & Wong, C. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b03729 · Cited by 44
Kao, D., Lux, A., Schaffert, A., Lang, R., Altmann, F., & Nimmerjahn, F. (2017) · European Journal of Immunology · doi:10.1002/eji.201747208 · Cited by 48
Blondeel, E. J. M., & Aucoin, M. G. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.06.008 · Cited by 46
“ADCC No observed relationship between galactosylation and in vitro ADCC (Boyd et al., 1995; Shinkawa et al., 2003) ACCEPTED MANUSCRIPT”
BackgroundMethodDiversity in structure and functions of antibody sialylation in the Fc
Raju, T. S., & Lang, S. E. (2014) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2014.06.014 · Cited by 46
“Functional diversity of Fc sialylation The presence of core fucose residue has been shown to reduce ADCC activity of IgGs [30,31].”
BackgroundKamoda, S., & Kakehi, K. (2008) · Electrophoresis · doi:10.1002/elps.200700940 · Cited by 45
del Val, I. J., Kyriakopoulos, S., Polizzi, K. M., & Kontoravdi, C. (2013) · Analytical Biochemistry · doi:10.1016/j.ab.2013.09.005 · Cited by 45
van Berkel, P. H. C., Gerritsen, J., van Voskuilen, E., Perdok, G. J., Vink, T., van de Winkel, J. G. J., & Parren, P. W. H. I. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22535 · Cited by 53
“…reported for IgG obtained via cotransfection with the acetyl-glycosaminyltransferase-III gene (Davies et al., 2001; Schuster et al., 2005) were about 10-fold, while about 50-fold improvement was obtained using production cell lines deficient for FUT8 (Shields et al., 2002; Shinkawa et al., 2003).”
BackgroundMethodExploring the Potential of Monoclonal Antibody Therapeutics for HIV-1 Eradication
Euler, Z., & Alter, G. (2014) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2014.0235 · Cited by 47
Greville, G., McCann, A. H., Rudd, P. M., & Saldova, R. (2016) · Epigenetics · doi:10.1080/15592294.2016.1241932 · Cited by 44
“Lack of core fucose enhances antibody-dependent cellular cytotoxicity 50–100%.(71) Terminal”
BackgroundDivergent Chemoenzymatic Synthesis of Asymmetrical‐Core‐Fucosylated and Core‐Unmodified N‐Glycans
Li, T., Huang, M., Liu, L., Wang, S., Moremen, K. W., & Boons, G. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201604999 · Cited by 46
Sialylated immunoglobulin G: a promising diagnostic and therapeutic strategy for autoimmune diseases
Li, D., Lou, Y., Zhang, Y., Liu, S., Li, J., & Tao, J. (2021) · Theranostics · doi:10.7150/thno.53961 · Cited by 48
“The affinity of core-fucosylated IgG1 for FcγRIIIa is 100-fold lower than that of the defucosylated version due to the steric hindrance between the Asn162-glycan of FcγRIIIa and the Asn297-linked carbohydrate of Fc chain A [49].”
BackgroundInfluentialAntibody therapy for Adult T-cell leukemia–lymphoma
Ishida, T., & Ueda, R. (2011) · International Journal of Hematology · doi:10.1007/s12185-011-0941-5 · Cited by 45
“Of all the sugar components in the oligosaccharide, galactose, bisecting-GlcNAc, and fucose [44, 45] have been reported to affect ADCC.”
BackgroundMabashi‐Asazuma, H., Kuo, C.-W., Khoo, K., & Jarvis, D. L. (2013) · Glycobiology · doi:10.1093/glycob/cwt161 · Cited by 48
“…vector encoding anti-CD20-IgG produced a nonfucosylated form of this antibody, which is expected to have enhanced effector function, based on a significant body of previous literature (Shields et al. 2002; Shinkawa et al. 2003; Li et al. 2013; reviewed by Lim et al. 2010; Owen and Stewart 2012).”
BackgroundInfluentialEffect of high mannose glycan pairing on IgG antibody clearance
Liu, D., & Flynn, G. C. (2016) · Biologicals · doi:10.1016/j.biologicals.2016.02.003 · Cited by 49
Glycosylation of FcγRIII in N163 as mechanism of regulating receptor affinity
Drescher, B., Witte, T., & Schmidt, R. E. (2003) · Immunology · doi:10.1046/j.1365-2567.2003.01743.x · Cited by 44
Increased bisecting and core-fucosylated N-glycans on mutant human amyloid precursor proteins
Akasaka‐Manya, K., Manya, H., Sakurai, Y., Wójczyk, B. S., Spitalnik, S. L., & Endo, T. (2008) · Glycoconjugate Journal · doi:10.1007/s10719-008-9140-x · Cited by 45
Conserved FcγR- glycan discriminates between fucosylated and afucosylated IgG in humans and mice
Dekkers, G., Bentlage, A. E. H., Plomp, R., Visser, R., Koeleman, C. A. M., Beentjes, A., Mok, J. Y., van Esch, W. J. E., Wuhrer, M., Rispens, T., et al. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.12.006 · Cited by 49
“Furthermore, this affinity is also influenced by the composition of the conserved glycan at position Asn297 in the Fc of IgG (Dekkers et al., 2017b; Jefferis, 2009; Shields et al., 2002; Shinkawa et al., 2003; Subedi and Barb, 2015; Yasuma et al., 2016).”
BackgroundMarcucci, F., Bellone, M., Rumio, C., & Corti, A. (2013) · mAbs · doi:10.4161/mabs.22775 · Cited by 45
Galactosyltransferase 4 is a major control point for glycan branching in N-linked glycosylation
McDonald, A. G., Hayes, J. M., Bezak, T., Gluchowska, S. A., Cosgrave, E. F. J., Struwe, W. B., Stroop, C. J. M., Kok, H. J., van de Laar, T., Rudd, P. M., et al. (2014) · Journal of Cell Science · doi:10.1242/jcs.151878 · Cited by 49
“…lacking core fucosylation, resulting in a 50–100-fold higher affinity for Fcc receptors and a concomitant increase in antibody-dependent cellular cytotoxicity (ADCC) (Ferrara et al., 2011; Ferrara et al., 2006; Iida et al., 2006; Shields et al., 2002; Shinkawa et al., 2003; Umaña et al., 1999).”
BackgroundGlycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties
Luo, C., Chen, S., Xu, N., Wang, C., Sai, W. B., Zhao, W., Li, Y. C., Hu, X. J., Tian, H., Gao, X. D., et al. (2017) · Scientific Reports · doi:10.1038/srep46347 · Cited by 41
Engineering of Yeast Glycoprotein Expression
Wachter, C. D., Landuyt, L. V., & Callewaert, N. (2018) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2018_69 · Cited by 54
Streptococcus pyogenes evades adaptive immunity through specific IgG glycan hydrolysis
Naegeli, A., Bratanis, E., Karlsson, C. A. Q., Shannon, O., Kalluru, R. S., Linder, A., Malmström, J. A., & Collin, M. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190293 · Cited by 49
“For example, IgGs lacking core fucosylation exhibit increased affinity for FcγRIIIA and are therefore significantly more potent in eliciting antibody-dependent cellular cytotoxicity (Shinkawa et al., 2003; Okazaki et al., 2004).”
BackgroundMogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas
Moore, D. C., Elmes, J. B., Shibu, P. A., Larck, C., & Park, S. I. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019884863 · Cited by 50
“The lack of fucosylation enhances the antibody-dependent cellular cytotoxicity of mogamulizumab to CCR4-positive cells, offering it a mechanistic advantage compared with conventionally glycosylated monoclonal antibodies.(25) Also, by depleting CCR4-positive regulatory T-cells, it is thought that mogamulizumab can enha…”
BackgroundSynthetic glycobiology: exploits in the Golgi compartment
Czlapinski, J. L., & Bertozzi, C. R. (2006) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2006.10.009 · Cited by 49
The potential of engineered antibodies for HIV-1 therapy and cure
Grobben, M., Stuart, R. A., & van Gils, M. J. (2019) · Current Opinion in Virology · doi:10.1016/j.coviro.2019.07.007 · Cited by 47
Zhang, D., Chen, B., Wang, Y., Xia, P., He, C., Liu, Y., Zhang, R., Zhang, M., & Li, Z. (2016) · Scientific Reports · doi:10.1038/srep25957 · Cited by 46
Nakayama, K., Wakamatsu, K., Fujii, H., Shinzaki, S., Takamatsu, S., Kitazume, S., Kamada, Y., Takehara, T., Taniguchi, N., & Miyoshi, E. (2018) · The Journal of Biochemistry · doi:10.1093/jb/mvy098 · Cited by 42
Natsume, A., Wakitani, M., Yamane-Ohnuki, N., Shoji-Hosaka, E., Niwa, R., Uchida, K., Satoh, M., & Shitara, K. (2006) · The Journal of Biochemistry · doi:10.1093/jb/mvj157 · Cited by 42
Self-citationDevelopment of Antibodies and Chimeric Molecules for Cancer Immunotherapy
Waldmann, T. A., & Morris, J. C. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90003-0 · Cited by 47
Modulating antibody effector functions by Fc glycoengineering
García-Alija, M., Moer, B. V., Sastre, D. E., Azzam, T., Du, J. J., Trastoy, B., Callewaert, N., Sundberg, E. J., & Guerin, M. E. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108201 · Cited by 47
Structural mechanism of high affinity Fcγ RI recognition of immunoglobulin G
Lu, J., & Sun, P. D. (2015) · Immunological Reviews · doi:10.1111/imr.12346 · Cited by 44
“The structural and conformation role of Fc glycans, however, could not explain the known observation of fucosylation-associated reduction of antibody recognition by Fcc receptors (34, 35).”
BackgroundNett, J. H., Stadheim, T. A., Li, H., Bobrowicz, P., Hamilton, S. R., Davidson, R. C., Choi, B., Mitchell, T., Bobrowicz, B., Rittenhour, A. M., et al. (2011) · Yeast · doi:10.1002/yea.1835 · Cited by 48
“The bisecting GlcNAc has been implicated in the modulation of antibody-dependent cellular cytotoxicity (ADCC) (Umana et al., 1999; Davies et al., 2001; Shinkawa et al., 2003) and might be a potential way to generate antibodies with optimized effector functions.”
Impact of cell culture on recombinant monoclonal antibody product heterogeneity
Liu, H., Nowak, C., Shao, M., Ponniah, G., & Neill, A. (2016) · Biotechnology Progress · doi:10.1002/btpr.2327 · Cited by 47
Li, W., Wu, Y., Kong, D., Yang, H., Wang, Y., Shao, J., Feng, Y., Chen, W., Ma, L., Ying, T., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-07966-3 · Cited by 42
“Our antibody domains are also devoid of N-glycosylation, i.e., they do not contain glycans (as Fc does) which could complicate IgG-Fc mediated ADCC by different glycoforms 32 .”
BackgroundGu, W., Fukuda, T., Isaji, T., Hashimoto, H., Wang, Y., & Gu, J. (2013) · The FASEB Journal · doi:10.1096/fj.12-225805 · Cited by 43
Constrained global sensitivity analysis for bioprocess design space identification
Kotidis, P., Demis, P., Goey, C. H., Correa, E., McIntosh, C., Trepekli, S., Shah, N., Klymenko, O. V., & Kontoravdi, C. (2019) · Computers & Chemical Engineering · doi:10.1016/j.compchemeng.2019.01.022 · Cited by 40
Vestrheim, A., Moen, A. R., Egge-Jacobsen, W. M., Reubsaet, L., Halvorsen, T. G., Bratlie, D. B., Paulsen, B. S., & Michaelsen, T. E. (2014) · Immunity Inflammation and Disease · doi:10.1002/iid3.22 · Cited by 39
Immunoglobulin Glycosylation Effects in Allergy and Immunity
Epp, A., Locker, K. C. S., Herr, A. B., & Strait, R. T. (2016) · Current Allergy and Asthma Reports · doi:10.1007/s11882-016-0658-x · Cited by 45
Bardhi, A., Wu, Y., Chen, W., Li, W., Zhu, Z., Zheng, J. H., Wong, H. C., Jeng, E. K., Jones, J., Ochsenbauer, C., et al. (2017) · Journal of Virology · doi:10.1128/jvi.00937-17 · Cited by 40
“Defucosylation of the Fc domains of antibodies increases their affinity toward Fc RIIIa expressed by NK cells and macrophages and thereby significantly amplifies their capacity to mediate ADCC (14, 15) and eliminate tumor cells in cancer patients (16–18).”
BackgroundHilliard, M., Alley, W. R., McManus, C. A., Yu, Y. Q., Hallinan, S., Gebler, J. C., & Rudd, P. M. (2017) · mAbs · doi:10.1080/19420862.2017.1377381 · Cited by 48
Tomida, S., Takata, M., Hirata, T., Nagae, M., Nakano, M., & Kizuka, Y. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013079 · Cited by 41
“Additionally, removal of core fucose from IgG1 drastically enhances the antibody-dependent cellular cytotoxicity (18).”
BackgroundExtending the Martini Coarse-Grained Force Field to N -Glycans
Shivgan, A. T., Marzinek, J. K., Huber, R. G., Krah, A., Henchman, R. H., Matsudaira, P., Verma, C. S., & Bond, P. J. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00495 · Cited by 40
Liu, S., & Liu, X. (2021) · Advances in clinical chemistry · doi:10.1016/bs.acc.2021.02.001 · Cited by 44
Pietro, A. D., Polmear, J., Cooper, L., Damelang, T., Hussain, T., Hailes, L., O’Donnell, K., Udupa, V., Tian, M., Preston, S., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01077-y · Cited by 42
L‐fucose, a sugary regulator of antitumor immunity and immunotherapies
Adhikari, E., Liu, Q., Burton, C., Mockabee‐Macias, A., Lester, D. K., & Lau, E. K. (2022) · Molecular Carcinogenesis · doi:10.1002/mc.23394 · Cited by 45
Core Fucosylation Regulates the Function of Pre-BCR, BCR and IgG in Humoral Immunity
Sun, Y., Li, X., Wang, T., & Li, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844427 · Cited by 46
Firth, D. F., Bell, L., Squires, M., Estdale, S., & McKee, C. (2015) · Analytical Biochemistry · doi:10.1016/j.ab.2015.06.001 · Cited by 42
Glycosylation of Natural and Recombinant Antibody Molecules
Jefferis, R. (2005) · Advances in experimental medicine and biology · doi:10.1007/0-387-25515-x_26 · Cited by 47
“Dramatic increases in FccRIII mediated ADCC efficacy have been reported for glycoforms of antibodies lacking core fucose [15–17].”
BackgroundNatsume, A., Shimizu‐Yokoyama, Y., Satoh, M., Shitara, K., & Niwa, R. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01327.x · Cited by 45
Self-citationKircheis, R., Halanek, N., Koller, I., Jost, W. H., Schuster, M., Gorr, G., Hajszan, K., & Nechansky, A. (2012) · mAbs · doi:10.4161/mabs.20577 · Cited by 41
Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse
Vincent, M., Teppaz, G., Lajoie, L., Solé-Jamault, V., Bessard, A., Maillasson, M., Loisel, S., Béchard, D., Clemenceau, B., Thibault, G., et al. (2014) · mAbs · doi:10.4161/mabs.28699 · Cited by 38
An innovative approach for the characterization of the isoforms of a monoclonal antibody product
Sundaram, S., Matathia, A. M., Qian, J., Zhang, J., Hsieh, M.-C., Liu, T., Crowley, R., Parekh, B. S., & Zhou, Q. (2011) · mAbs · doi:10.4161/mabs.3.6.18090 · Cited by 39
Glycoengineering design options for IgG1 in CHO cells using precise gene editing
Schulz, M. A., Tian, W., Mao, Y., Coillie, J. V., Sun, L., Larsen, J. S., Chen, Y., Kristensen, C., Vakhrushev, S. Y., Clausen, H., et al. (2018) · Glycobiology · doi:10.1093/glycob/cwy022 · Cited by 42
Scherer, H. U., Wang, J., Toes, R. E. M., van der Woude, D., Koeleman, C. A. M., de Boer, A. R., Huizinga, T. W. J., Deelder, A. M., & Wuhrer, M. (2008) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200800098 · Cited by 41
Insect cells for antibody production: Evaluation of an efficient alternative
Palmberger, D., Rendić, D., Tauber, P., Krammer, F., Wilson, I. B. H., & Grabherr, R. M. (2011) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2011.02.009 · Cited by 48
Castro, L. G., Cogo, N. P., & Volk, L. B. D. S. (2006) · Revista Brasileira de Ciência do Solo · doi:10.1590/s0100-06832006000200014 · Cited by 78
Distinct Fcα receptor N-glycans modulate the binding affinity to immunoglobulin A (IgA) antibodies
Göritzer, K., Turupcu, A., Maresch, D., Novák, J., Altmann, F., Oostenbrink, C., Obinger, C., & Strasser, R. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.009954 · Cited by 41
Analysis of O-glycoforms of the IgA1 hinge region by sequential deglycosylation
Ohyama, Y., Yamaguchi, H., Nakajima, K., Mizuno, T., Fukamachi, Y., Yokoi, Y., Tsuboi, N., Inaguma, D., Hasegawa, M., Renfrow, M. B., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-57510-z · Cited by 42
Conner, K. P., Devanaboyina, S. C., Thomas, V. A., & Rock, D. A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107574 · Cited by 41
Cao, L., Lih, T. M., Hu, Y., Schnaubelt, M., Chen, S., Zhou, Y., Guo, C., Dong, M., Yang, W., Eguez, R. V., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31472-4 · Cited by 39
Targeted glycoengineering extends the protein N-glycosylation pathway in the silkworm silk gland
Mabashi‐Asazuma, H., Sohn, B.-H., Kim, Y., Kuo, C., Khoo, K., Kucharski, C. A., Fraser, M. J., & Jarvis, D. L. (2015) · Insect Biochemistry and Molecular Biology · doi:10.1016/j.ibmb.2015.07.004 · Cited by 38
“This is important because core fucosylation of the Fc N-glycan represses antibody effector functions, such as antibodydependent cell cytotoxicity (Shinkawa et al., 2003).”
BackgroundGlycoengineering Chinese hamster ovary cells: a short history
Donini, R., Haslam, S. M., & Kontoravdi, C. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200840 · Cited by 37
Monoclonal anti-D antibodies to prevent alloimmunization: lessons from clinical trials
Béliard, R. (2006) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2006.03.013 · Cited by 37
Enhancing the Quality of Antibodies to HIV-1 Envelope by GagPol-Specific Th Cells
Bonsmann, M. S. G., Niezold, T., Temchura, V., Pissani, F., Ehrhardt, K., Brown, E. P., Osei‐Owusu, N. Y., Hannaman, D., Hengel, H., Ackerman, M. E., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501377 · Cited by 46
The Role of Fc Gamma Receptors in Broad Protection against Influenza Viruses
Thulin, N. K., & Wang, T. T. (2018) · Vaccines · doi:10.3390/vaccines6030036 · Cited by 36
“Absence of core fucose stabilizes the Fc-FcγRIIIa interaction through an unusual carbohydrate-carbohydrate interaction, resulting in enhanced activating signaling and effector functions [13,14].”
BackgroundRoberts, J. T., & Barb, A. W. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005273 · Cited by 47
Molecular modeling of antibodies for the treatment of TNF α ‐related immunological diseases
Pierri, C. L., Bossis, F., Punzi, G., Grassi, A., Cetrone, M., Parisi, G., & Tricarico, D. (2016) · Pharmacology Research & Perspectives · doi:10.1002/prp2.197 · Cited by 40
“1 | e00197 Page 1”
Humanized Mice to Study FcγR Function
Bournazos, S., DiLillo, D. J., & Ravetch, J. V. (2014) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-07911-0_11 · Cited by 39
Sun, T., Li, C., Han, L., Jiang, H., Xie, Y., Zhang, B., Qian, X., Lu, H., & Zhu, J. (2015) · Engineering in Life Sciences · doi:10.1002/elsc.201400218 · Cited by 40
Agarabi, C. D., Schiel, J. E., Lute, S. C., Chavez, B. K., Boyne, M. T., Brorson, K., Khan, M. A., & Read, E. K. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24420 · Cited by 39
Zhang, Z., Zhang, Y., Sun, Q., Feng, F., Huhe, M., Li, M., & Chen, Z. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0104 · Cited by 34
“Previous studies have demonstrated that Fc receptor-mediated ADCC depends significantly on the patterns of Fc glycosylation and that a fucose-negative antibody exhibits enhanced binding affinity to FcgRIIIA, with significantly increasedbinding toNK cells, whichpromoteADCCefficacy (27).”
BackgroundClinical Application of Anti-CCR4 Monoclonal Antibody
Ueda, R. (2015) · Oncology · doi:10.1159/000431059 · Cited by 40
Li, W., Liu, Q., Pang, Y., Jin, J., Wang, H., Cao, H., Li, Z., Wang, X., Ma, B., Yan, C., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.303123 · Cited by 36
Dojima, T., Nishina, T., Kato, T., Uno, T., Yagi, H., Kato, K., & Park, E. Y. (2009) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2009.06.013 · Cited by 36
“This is favorable for therapeutic antibody IgG production, because antibody-dependent cellular cytotoxicity is enhanced by defucosylation of complex type N-glycans (Shinkawa et al., 2003).”
BackgroundChapter 2 Human Total Serum N‐Glycome
(2008) · Advances in clinical chemistry · doi:10.1016/s0065-2423(08)00402-2 · Cited by 36
Kaneko, M. K., Suzuki, H., Ohishi, T., Nakamura, T., Tanaka, T., & Kato, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031941 · Cited by 37
“Furthermore, a core fucose deficiency on the Fc N -glycan has been shown to enhance the binding of IgG to Fc γ R on effector cells [25] and exert potent antitumor effects [26].”
BackgroundEnhanced sialylation of a human chimeric IgG1 variant produced in human and rodent cell lines
Mimura, Y., Kelly, R. M., Unwin, L., Albrecht, S., Jefferis, R., Goodall, M., Mizukami, Y., Mimura-Kimura, Y., Matsumoto, T., Ueoka, H., et al. (2016) · Journal of Immunological Methods · doi:10.1016/j.jim.2015.11.009 · Cited by 35
“Importantly, outer-arm sugar residues are involved in unique functions of IgG-Fc glycoforms including enhanced ADCC activity of non-fucosylated glycoforms (Shields et al., 2002; Shinkawa et al., 2003).”
BackgroundSoleimanpour, S., Hassannia, T., Mahdieh, M., Amini, A. A., & Rezaee, S. A. (2016) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2016.1163323 · Cited by 35
Mogamulizumab for the treatment of T-cell lymphoma
Makita, S., & Tobinai, K. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1347634 · Cited by 42
Itai, S., Ohishi, T., Kaneko, M. K., Yamada, S., Abe, S., Nakamura, T., Yanaka, M., Chang, Y.-W., Ohba, S., Nishioka, Y., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25132 · Cited by 35
“Then, we produced a non-fucosylated version of 47-mG2a (47-mG2a-f) to augment its ADCC activities because nonfucosylated antibodies are known to show higher ADCC activities [35, 50].”
Muñoz, M. E. C., Valenzuela‐Vázquez, L., Sánchez‐Herrera, J., & Tapia, J. S.-O. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0618-224rr · Cited by 38
Patel, K., Nott, J. D., & Barb, A. W. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra119.001607 · Cited by 43
“Of the potential modifications to the Fc N-glycan, fucosylation of the core N-acetylglucosamine (GlcNAc) residue occurs at high levels in human serum ( 85– 95%) though antibodies lacking this modification bind CD16a with higher affinity and elicit antibody-dependent cell-mediated cytotoxicity at lower antibody concent…”
BackgroundThe Core Fucose on an IgG Antibody is an Endogenous Ligand of Dectin‐1
Manabe, Y., Marchetti, R., Takakura, Y., Nagasaki, M., Nihei, W., Takebe, T., Tanaka, K., Kabayama, K., Chiodo, F., Hanashima, S., et al. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201911875 · Cited by 35
Martin, T. C., Ilieva, K. M., Visconti, A., Beaumont, M., Kiddle, S. J., Dobson, R., Mangino, M., Lim, E. M., Pezer, M., Steves, C. J., et al. (2020) · Cells · doi:10.3390/cells9030665 · Cited by 38
Shoji-Hosaka, E., Kobayashi, Y., Wakitani, M., Uchida, K., Niwa, R., Nakamura, K., & Shitara, K. (2006) · The Journal of Biochemistry · doi:10.1093/jb/mvj207 · Cited by 35
Self-citationGuo, N., Liu, Y., Masuda, Y., Kawagoe, M., Ueno, Y., Kameda, T., & Sugiyama, T. (2004) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2004.10.002 · Cited by 38
Peptide-displaying phage technology in glycobiology
Fukuda, M. (2011) · Glycobiology · doi:10.1093/glycob/cwr140 · Cited by 36
Kommineni, V., Markert, M., Ren, Z., Palle, S., Carrillo, B., Deng, J., Tejeda, A., Nandi, S., McDonald, K. A., Marcel, S., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010194 · Cited by 39
“It is expected that the reason for this increased ADCC activity lies in the absence of fucose residues on the glycosylation core rather than the high content of mannose residues, as many studies have reported the effect of afucosylation on the ADCC activity of anti-cancer antibodies [54] including rituximab [10,20,55,…”
Background
Metadata
- Authors
- Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., Hanai, N., & Shitara, K.
- Affiliations
- Kyowa Kirin (Japan) (JP)
- Corresponding author
- Shitara, Kenya
- ORCID
- Uchida, Kazuhisa
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-01
- Volume
- 278
- Issue
- 5
- Pages
- 3466-3473
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2084136419
- Cited by
- 1,413
- References
- 33
- Citations by year
- 2026: 37 · 2025: 47 · 2024: 55 · 2023: 45 · 2022: 77 · 2021: 78 · 2020: 87 · 2019: 70 · 2018: 83 · 2017: 77 · 2016: 71 · 2015: 72 · 2014: 78 · 2013: 56 · 2012: 67
- FWCI
- 14.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6498 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- antibody-dependent cellular cytotoxicity, fucosylation, bisecting N-acetylglucosamine, galactose, FUT8, alpha-1,6-fucosyltransferase, humanized monoclonal antibody, CHO cell expression, antibody glycosylation, therapeutic antibodies
- MeSH terms
- Acetylglucosamine, Animals, Antibody-Dependent Cell Cytotoxicity, Base Sequence, Carbohydrate Conformation, Carbohydrate Sequence, Cell Line, Chromatography, Affinity, Fucose, Galactose, Cricetinae, Humans, Immunoglobulin G, Molecular Sequence Data, Oligosaccharides, Recombinant Fusion Proteins, Transfection, Polymerase Chain Reaction, CHO Cells, DNA Primers, Lectins, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.